Sixty-seven oncology physician group practices in 37 states will participate in the Enhanced Oncology Model, a voluntary five-year payment model that will begin July 1 for beneficiaries who receive systemic chemotherapy, the Centers for Medicare & Medicaid Services announced yesterday. The Center for Medicare and Medicaid Innovation model supports the administration’s moonshot goal to reduce cancer death rates by 50% over the next 25 years. Participating practices must provide 24/7 access to care, patient navigation and care planning; use certified electronic health record technology, evidence-based guidelines, electronic patient reported outcomes and data to improve quality; and must also screen for health-related social needs. The model will qualify as an alternative payment model under the Quality Payment Program’s Merit-based Incentive Payment System beginning in July. It offers two levels of downside risk, with the higher risk arrangement excluded from MIPS reporting requirements and payment adjustments as an Advanced APM. For more, see the model’s updated fact sheet.

Related News Articles

Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…